Confidence-Building Measure G

Vaccine production facilities

Clinical trial material only, no own licenses for marketing: produces RNA vaccines encoding Corona, Ebola, Marburg or Lassavirus antigens.

Manufacture of live recombinant Ebola virus vaccines.

Develops and produces RNA vaccines encoding Rabies antigens and SARS-CoV-2 antigens.

Hepatitis B (commissioned production, no own licence for marketing)

Influenza virus vaccine for human immunisation purposes

Vaccines concentrates (bulk) against diphtheria, tetanus, rabies, tick-borne encephalitis, mumps are produced in Marburg. These products are formulated in Marburg. Final vaccines formulation and filling is performed at another GSK site. Vaccines concentrate (bulk) for Meningococcus meningitis serumgroup A is formulated and lyophilised in Marburg.
Final packaging with formulated serumgroups C, W, Y is performed at another GSK site.

Live Smallpox vaccines, Following Investigational Medicinal Products - live recombinant HIV vaccines, live recombinant Malaria vaccines, live recombinant and inactivated recombinant Filovirus vaccines, live recombinant Flavivirus vaccines, MERS-CoV vaccine, inactivated recombinant Lassa virus vaccine, live recombinant Rift Valley Fever Virus vaccine, live recombinant SARS-CoV-2 vaccines and live recombinant Chikungunya vaccine

produces mRNA vaccines encoding SARS-CoV-2 antigens

Clinical trial material only, no own licenses for marketing: Tuberculosis vaccine (recombinant and non-recombinant). Smallpox vaccine (recombinant), Bordetella vaccine, HIV vaccine (recombinant), Zika vaccine (recombinant), Typhus vaccine, RSV, Newcastle Disease Virus (Drug Substance, recombinant), Influenza A (PR8 vaccine), VSV vaccine (recombinant), HSV-1 vaccine (recombinant), CoVid vaccine (recombinant)